Dr. Lesley Tilson:

That is happening.

Since that meeting in 2018, there has been a European health technology assessment, HTA, regulation, whereby all European countries are doing joint comparative clinical assessments. That is the next step following the European Medicines Agency licence, where there is a comparative assessment of the drug versus the current standard of care in a particular country. That is starting to happen. The NCPE is playing a leading role in that. We are currently taking part in two of these joint clinical assessments, which are Europe-wide.